The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Single‐agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%–40% of patients achieve stable disease. The primary objective was to estimate progression‐free survival (PFS) after sequential versus combination cytotoxic T‐lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum‐resistant high‐grade...
Background
Patients with ovarian cancer often present with late‐stage disease and nonspecific symptoms, but little is known about factors affecting the time to diagnosis (TTD) in the United States.
Methods
A retrospective, population‐based study of the Surveillance, Epidemiology, and End Results–Medicare database was conducted. It included women 66 years old or older with stage II to IV epithelial...
BACKGROUNDA 2‐stage ovarian cancer screening strategy was evaluated that incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to estimate risk of ovarian cancer. Women with high‐risk scores were referred for transvaginal ultrasound (TVS).
METHODSA single‐arm, prospective study of postmenopausal women was conducted. Participants underwent an annual CA125 blood test. Based...
BACKGROUND:A study was undertaken to use the 2‐tier system to reclassify the grade of serous ovarian tumors previously classified using the International Federation of Gynecology and Obstetrics (FIGO) 3‐tier system and determine the progression‐free survival (PFS) and overall survival (OS) of patients treated on Gynecologic Oncology Group (GOG) Protocol 158.
METHODS:The authors retrospectively reviewed...
BACKGROUND:Low‐grade serous carcinoma (LGSC) of the ovary is a rare tumor that is distinct from its high‐grade counterpart. The objective of this study was to determine whether patient demographic factors and clinical treatment histories affected survival in a population of women with LGSC.
METHODS:A review of patients who had pathologically confirmed LGSC of the ovary diagnosed between 1977 and...
BACKGROUND:Women who are at high risk for breast and ovarian cancer have 2 major management options to reduce their risk of ovarian cancer: periodic screening (PS) or risk‐reducing salpingo‐oophorectomy (RRSO). Little is known regarding patient satisfaction levels with risk‐reduction strategies. Thus, the authors sought to determine levels of patient satisfaction with PS versus RRSO and to identify...
BACKGROUND:The incidence of pelvic fractures and associated risk factors was determined in women treated with curative‒intent radiotherapy for cervical cancer.
METHODS:The records of 516 women treated with curative‒intent radiotherapy for cervical cancer between 2001 and 2006 at the University of Texas M. D. Anderson Cancer Center were reviewed. Among these, 300 patients had at least 1 post‐treatment...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.